Abstract
Apoptosis is an essential and highly conserved process for the maintenance of tissue homeostasis and involves a programmed series of events for the removal of effete, damaged, or mutated cells. Although, activation of caspases underscores the classical signaling cascade during apoptotic execution the role of caspase-independent mechanisms in apoptosis has also gained recognition. It is now well established that apoptotic execution is an inherent tumor suppressor mechanism and failure of apoptosis invariably leads to the acquisition of the transformed phenotype. Indeed, resistance to apoptosis is an essential acquired trait that facilitates the processes of tumor initiation and progression. As a matter of fact, efficient death execution could be a critical even at an earlier stage to inhibit tumor promotion. Interestingly, there is a school of thought supported by strong data that an altered redox status and intracellular milieu of cells could provide the seeding ground for tumor promotion and initiation, and at a latter stage tumor maintenance/progression, by blunting cell death signaling. These findings have not only enhanced our understanding of the processes of carcinogenesis and drug resistance but, more importantly provide novel targets for designing strategies to overcome the problem of apoptosis resistance in tumor cells. This review focuses on the pathways of apoptotic execution, and discusses the role of intracellular redox status on cell survival and death signaling in tumor cells.
Keywords: death effector domains (DED), reactive oxygen species (ROS), oligomerization, pro-oxidant state, Carcinogenesis
Current Pharmaceutical Design
Title: Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets
Volume: 12 Issue: 34
Author(s): Shazib Pervaiz
Affiliation:
Keywords: death effector domains (DED), reactive oxygen species (ROS), oligomerization, pro-oxidant state, Carcinogenesis
Abstract: Apoptosis is an essential and highly conserved process for the maintenance of tissue homeostasis and involves a programmed series of events for the removal of effete, damaged, or mutated cells. Although, activation of caspases underscores the classical signaling cascade during apoptotic execution the role of caspase-independent mechanisms in apoptosis has also gained recognition. It is now well established that apoptotic execution is an inherent tumor suppressor mechanism and failure of apoptosis invariably leads to the acquisition of the transformed phenotype. Indeed, resistance to apoptosis is an essential acquired trait that facilitates the processes of tumor initiation and progression. As a matter of fact, efficient death execution could be a critical even at an earlier stage to inhibit tumor promotion. Interestingly, there is a school of thought supported by strong data that an altered redox status and intracellular milieu of cells could provide the seeding ground for tumor promotion and initiation, and at a latter stage tumor maintenance/progression, by blunting cell death signaling. These findings have not only enhanced our understanding of the processes of carcinogenesis and drug resistance but, more importantly provide novel targets for designing strategies to overcome the problem of apoptosis resistance in tumor cells. This review focuses on the pathways of apoptotic execution, and discusses the role of intracellular redox status on cell survival and death signaling in tumor cells.
Export Options
About this article
Cite this article as:
Pervaiz Shazib, Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets, Current Pharmaceutical Design 2006; 12 (34) . https://dx.doi.org/10.2174/138161206779010503
DOI https://dx.doi.org/10.2174/138161206779010503 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor
Current Pharmaceutical Design FAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Meet Our Editorial Board Member
Current Medical Imaging Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Intraoperative Magnetic Resonance Imaging
Current Medical Imaging Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology MicroRNA-7 Regulates Insulin Signaling Pathway by Targeting IRS1, IRS2, and RAF1 Genes in Gestational Diabetes Mellitus
MicroRNA Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
Current Pharmaceutical Design